163 related articles for article (PubMed ID: 32307868)
1. In Situ Synthesis of an Aptamer-Based Polyvalent Antibody Mimic on the Cell Surface for Enhanced Interactions between Immune and Cancer Cells.
Shi P; Wang X; Davis B; Coyne J; Dong C; Reynolds J; Wang Y
Angew Chem Int Ed Engl; 2020 Jul; 59(29):11892-11897. PubMed ID: 32307868
[TBL] [Abstract][Full Text] [Related]
2. Aptamer-Engineered Natural Killer Cells for Cell-Specific Adaptive Immunotherapy.
Yang S; Wen J; Li H; Xu L; Liu Y; Zhao N; Zeng Z; Qi J; Jiang W; Han W; Zu Y
Small; 2019 May; 15(22):e1900903. PubMed ID: 31026116
[TBL] [Abstract][Full Text] [Related]
3. Equipping Natural Killer Cells with Specific Targeting and Checkpoint Blocking Aptamers for Enhanced Adoptive Immunotherapy in Solid Tumors.
Zhang D; Zheng Y; Lin Z; Liu X; Li J; Yang H; Tan W
Angew Chem Int Ed Engl; 2020 Jul; 59(29):12022-12028. PubMed ID: 32246555
[TBL] [Abstract][Full Text] [Related]
4. Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.
Smits NC; Coupet TA; Godbersen C; Sentman CL
Expert Opin Biol Ther; 2016 Sep; 16(9):1105-12. PubMed ID: 27248342
[TBL] [Abstract][Full Text] [Related]
5. Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide.
Kim JY; Bae JH; Lee SH; Lee EY; Chung BS; Kim SH; Kang CD
J Immunother; 2008 Jun; 31(5):475-86. PubMed ID: 18463537
[TBL] [Abstract][Full Text] [Related]
6. Cancer immunotherapy via nucleic acid aptamers.
Khedri M; Rafatpanah H; Abnous K; Ramezani P; Ramezani M
Int Immunopharmacol; 2015 Dec; 29(2):926-936. PubMed ID: 26603636
[TBL] [Abstract][Full Text] [Related]
7. Aptamer-based polyvalent ligands for regulated cell attachment on the hydrogel surface.
Gaddes ER; Gydush G; Li S; Chen N; Dong C; Wang Y
Biomacromolecules; 2015 Apr; 16(4):1382-9. PubMed ID: 25789558
[TBL] [Abstract][Full Text] [Related]
8. NK cell receptors as tools in cancer immunotherapy.
Sentman CL; Barber MA; Barber A; Zhang T
Adv Cancer Res; 2006; 95():249-92. PubMed ID: 16860660
[TBL] [Abstract][Full Text] [Related]
9. Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective.
Cifaldi L; Locatelli F; Marasco E; Moretta L; Pistoia V
Trends Mol Med; 2017 Dec; 23(12):1156-1175. PubMed ID: 29133133
[TBL] [Abstract][Full Text] [Related]
10. Enhancing anti-PD-1 Immunotherapy by Nanomicelles Self-Assembled from Multivalent Aptamer Drug Conjugates.
Geng Z; Wang L; Liu K; Liu J; Tan W
Angew Chem Int Ed Engl; 2021 Jul; 60(28):15459-15465. PubMed ID: 33904236
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological targeting of natural killer cells for cancer immunotherapy.
Miyazato K; Hayakawa Y
Cancer Sci; 2020 Jun; 111(6):1869-1875. PubMed ID: 32301190
[TBL] [Abstract][Full Text] [Related]
12. A New Ex Vivo Method for Effective Expansion and Activation of Human Natural Killer Cells for Anti-Tumor Immunotherapy.
Yang H; Tang R; Li J; Liu Y; Ye L; Shao D; Jin M; Huang Q; Shi J
Cell Biochem Biophys; 2015 Dec; 73(3):723-9. PubMed ID: 27259316
[TBL] [Abstract][Full Text] [Related]
13. Use of oligonucleotide aptamer ligands to modulate the function of immune receptors.
Gilboa E; McNamara J; Pastor F
Clin Cancer Res; 2013 Mar; 19(5):1054-62. PubMed ID: 23460536
[TBL] [Abstract][Full Text] [Related]
14. Reducing Toxicity of Immune Therapy Using Aptamer-Targeted Drug Delivery.
Gilboa E; Berezhnoy A; Schrand B
Cancer Immunol Res; 2015 Nov; 3(11):1195-200. PubMed ID: 26541880
[TBL] [Abstract][Full Text] [Related]
15. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
Hu W; Wang G; Huang D; Sui M; Xu Y
Front Immunol; 2019; 10():1205. PubMed ID: 31214177
[TBL] [Abstract][Full Text] [Related]
16. Cationic Nanoparticle-Mediated Activation of Natural Killer Cells for Effective Cancer Immunotherapy.
Kim KS; Han JH; Choi SH; Jung HY; Park JD; An HJ; Kim SE; Kim DH; Doh J; Han DK; Kim IH; Park W; Park KS
ACS Appl Mater Interfaces; 2020 Dec; 12(51):56731-56740. PubMed ID: 33290037
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more.
Chiossone L; Vienne M; Kerdiles YM; Vivier E
Semin Immunol; 2017 Jun; 31():55-63. PubMed ID: 28943093
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy.
Hu Y; Tian ZG; Zhang C
Acta Pharmacol Sin; 2018 Feb; 39(2):167-176. PubMed ID: 28880014
[TBL] [Abstract][Full Text] [Related]
19. Aptamer-enabled uptake of small molecule ligands.
Auwardt SL; Seo YJ; Ilgu M; Ray J; Feldges RR; Shubham S; Bendickson L; Levine HA; Nilsen-Hamilton M
Sci Rep; 2018 Oct; 8(1):15712. PubMed ID: 30356136
[TBL] [Abstract][Full Text] [Related]
20. Aptamers: A Feasible Technology in Cancer Immunotherapy.
Soldevilla MM; Villanueva H; Pastor F
J Immunol Res; 2016; 2016():1083738. PubMed ID: 27413756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
